201 related articles for article (PubMed ID: 32342945)
1. Early relapse after complete remission of primary plasma cell leukaemia manifesting clonal evolution: A case report.
Nyunt WWT; Abdul Jalil D; Zakariah NA; Abdul Karim N; Mohd Idris MR; Nasuruddin DN; Salwati SHUIB; Alauddin H; Tumian NR; Leong CF; Abdul Wahid SFS
Malays J Pathol; 2020 Apr; 42(1):143-150. PubMed ID: 32342945
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.].
Palazzo G
Recenti Prog Med; 2020 Mar; 111(3):160-166. PubMed ID: 32157264
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment with bortezomib-containing regimen of primary plasma cell leukemia: a case report.
Obeidat MB; Al-Swailmeen AM; Arabeat AM; Abukamar AS
Pan Afr Med J; 2020; 36():15. PubMed ID: 32774592
[TBL] [Abstract][Full Text] [Related]
5. Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
Ueda S; Kubo M; Matsuura N; Matsunaga H; Kataoka S; Maeda T; Inui Y; Kawata S; Kanakura Y
Intern Med; 2013; 52(11):1235-8. PubMed ID: 23728562
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
[TBL] [Abstract][Full Text] [Related]
7. [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
Hosono N; Yamauchi T; Nakamura T; Yamashita T; Ueda T
Gan To Kagaku Ryoho; 2008 Mar; 35(3):533-7. PubMed ID: 18347412
[TBL] [Abstract][Full Text] [Related]
8. [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
Telek B; Méhes L; Batár P; Kiss A; Udvardy M
Orv Hetil; 2008 Oct; 149(41):1957-9. PubMed ID: 18842514
[TBL] [Abstract][Full Text] [Related]
9. Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report.
Vo K; Guan T; Banerjee R; Lo M; Young R; Shah N
J Oncol Pharm Pract; 2022 Jul; 28(5):1244-1248. PubMed ID: 35084252
[TBL] [Abstract][Full Text] [Related]
10. Long term complete remission in primary plasma cell leukemia.
Tsuyuoka R; Takahashi T; Sasaki Y; Nakamura K; Fukumoto M; Kurisu Y; Tsubakimori K; Shioi K; Nakao K
Intern Med; 1995 Apr; 34(4):251-4. PubMed ID: 7606092
[TBL] [Abstract][Full Text] [Related]
11. Plasma cell leukaemia with t(11;14) not responsive to venetoclax.
Abu Zaanona MI; Patel P
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33495184
[TBL] [Abstract][Full Text] [Related]
12. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
13. Aggressive primary plasma cell leukemia with skin manifestations, trisomy 8 and molecular oligoclonal features.
Robak T; Urbańska-Rys H; Robak E; Bartkowiak J; Strzelecka B; Biernat W; Kordek R
Leuk Lymphoma; 2002 May; 43(5):1067-73. PubMed ID: 12148888
[TBL] [Abstract][Full Text] [Related]
14. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
15. Plasma Cell Leukaemia: A Rare Yet Aggressive Plasma Cell Dyscrasia With A Very Poor Response To Conventional Therapy.
Khan N; Raza SS; Khan UI; Hafez I; Abdullah MA; Hassan M; Rukh Hijaz AS; Hussain AK; Nadeem MD
J Ayub Med Coll Abbottabad; 2019; 31(2):272-275. PubMed ID: 31094130
[TBL] [Abstract][Full Text] [Related]
16. [Long-term complete remission in primary plasma cell leukemia after treatment with VAD chemotherapy and tandem autologous peripheral blood stem cell transplantation].
Iino M; Nakajima A; Shindo H
Gan To Kagaku Ryoho; 2008 Dec; 35(13):2441-3. PubMed ID: 19098420
[TBL] [Abstract][Full Text] [Related]
17. A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
Sekiguchi Y; Shimada A; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2014; 7(9):6313-22. PubMed ID: 25337285
[TBL] [Abstract][Full Text] [Related]
18. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
19. Plasma Cell Leukemia with Successful Upfront Venetoclax in Combination with Allogeneic Transplantation.
Tang ASO; Ahmad Asnawi AW; Koh AZY; Chong SL; Liew PK; Selvaratnam V; Md Fauzi A; Lau NS; Tan SM
Am J Case Rep; 2023 Mar; 24():e938868. PubMed ID: 36882990
[TBL] [Abstract][Full Text] [Related]
20. [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation].
Adam Z; Rehák Z; Koukalová R; Szturz P; Krejčí M; Pour L; Zahradová L; Moulis M; Kodet R; Nebeský T; Brejcha M; Adamová Z; Hájek R; Mayer J
Vnitr Lek; 2012 Jan; 58(1):62-71. PubMed ID: 22448704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]